An Overview on Evolving Role, Unmet Needs and Grey Areas in Anticoagulation in Cardiac Patients View PDF

Divya Viraajitha Vurutha
Medicine, NRI Institute Of Medical Science, India

Published on: 2024-09-06

Abstract

A number of cardiovascular diseases can be treated with anticoagulation, including acute myocardial infarction, percutaneous coronary intervention (PCI), stroke prophylaxis in patients with atrial arrhythmias, and mechanical heart valve patients. As a result of conflicting data supporting established agents and the rapid evolution of evidence-based practice that parallels the widespread use of new oral anticoagulants, clinical anticoagulation choices vary widely in the aforementioned diseases. Direct oral anticoagulants (DOACs) are discussed in this review, which summarizes evidence-based guidelines for their use in cardiovascular disease.

Keywords

Anticoagulation, Cardiovascular diseases, Cardiac patients, Myocardial infarction, Percutaneous coronary intervention, Stroke prophylaxis

Introduction

Cardiovascular disease management relies heavily on anticoagulation. A number of anticoagulation strategies have been developed within the last decade and have been tested in the treatment of acute coronary syndromes (ACS), PCI, atrial fibrillation (AF), cardioversions, and the replacement of cardiac valves. Anticoagulation strategies in cardiovascular disease must be adapted as data supporting novel anticoagulant uses emerge [1]. Here, we discuss the strengths and limitations of novel anticoagulation strategies in these settings, as well as provide a concise summary of the data supporting existing anticoagulation strategies [2]